PT - JOURNAL ARTICLE AU - DeForest, Natalie AU - Kavitha, Babu AU - Hu, Siqi AU - Isaac, Roi AU - Wang, Minxian AU - Du, Xiaomi AU - De Arruda Saldanha, Camila AU - Gylys, Jenny AU - Abagyan, Ruben AU - Najmi, Laeya AU - Mohan, Viswanathan AU - Alnylam Human Genetics AU - AMP-T2D Consortium AU - Flannick, Jason AU - Peloso, Gina M. AU - Gordts, Philip AU - Heinz, Sven AU - Deaton, Aimee M. AU - Khera, Amit V. AU - Olefsky, Jerrold AU - Radha, Venkatesan AU - Majithia, Amit R. TI - Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of multiple cardiovascular disease risk factors AID - 10.1101/2022.03.29.22273133 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.29.22273133 4099 - http://medrxiv.org/content/early/2022/03/30/2022.03.29.22273133.short 4100 - http://medrxiv.org/content/early/2022/03/30/2022.03.29.22273133.full AB - Loss-of-function mutations in Hepatocyte Nuclear Factor 1A (HNF1A) are known to cause rare forms of diabetes and alter hepatic physiology through unclear mechanisms. In the general population, 1:100 individuals carry a rare protein-coding variant in HNF1A, most of unknown functional consequence. To characterize the full allelic series, we performed deep mutational scanning of 11,970 protein-coding HNF1A variants in human hepatocytes and clinical correlation with 553,246 exome-sequenced individuals. Surprisingly, we found ∼1:5 rare protein-coding HNF1A variants found in the general population cause molecular gain-of-function (GOF), increasing the transcriptional activity of HNF1A by up to 50%. GOF in HNF1A conferred protection from type 2 diabetes (T2D) (OR=0.60, p=8.4 x 10-7), but not against coronary artery disease. Independently of T2D, increased hepatic expression of HNF1A promoted a pro-inflammatory and pro-atherogenic serum profile mediated in part by enhanced transcription of risk genes including PCSK9. In summary, ∼1:300 individuals carry a GOF variant in HNF1A that protects carriers from diabetes but enhances hepatic secretion of metabolic disease risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (1R03DK113328-01 and 1R01DK123422-01 to A.R.M, 1R01DK125490 to J.F and A.R.M), a UCSD/UCLA Pilot and Feasibility grant (P30 DK063491 to A.R.M), and a Ruth L. Kirschstein Institutional National Research Service Award T32 GM008666 from the National Institute of General Medical Sciences (to N.D.). S.H. received support from NIDDK grants P30DK063491 and P30DK120515, and NIGMS R01GM129523. G.M.P is supported by NHLBI grants R01HL142711 and R01HL127564. This publication includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll UK Biobank data used in this study are accessible through application to UK Biobank.